Physician profile
Luis Villa
NPI 1932197233
$1,324.31
in general payments reported to CMS, 2019-2025
20 companies · $649 in 2025
The $649 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $75.61 · 2021: $49.58 · 2022: $17.81 · 2023: $80.98 · 2024: $165 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.10 |
| Education | $123.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $275.98 | 2019-2025 | Rybrevant, Erleada |
| Astrazeneca Pharmaceuticals LP | $180.44 | 2025 | Enhertu, Calquence |
| Array Biopharma INC | $152.71 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Merck Sharp & Dohme LLC | $130.57 | 2020-2025 | Keytruda, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $129.41 | 2019-2024 | |
| Seagen INC. | $99.95 | 2025 | |
| Celgene Corporation | $55.51 | 2019-2020 | |
| Lilly USA, LLC | $49.11 | 2022-2024 | Verzenio |
| Pfizer INC. | $34.15 | 2024 | |
| Puma Biotechnology, INC. | $33.06 | 2023-2024 | |
| Daiichi Sankyo INC. | $26.46 | 2025 | Datroway |
| Pharmacosmos Therapeutics INC. | $22.65 | 2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $21.81 | 2025 | |
| Caris Mpi, INC. | $21.79 | 2025 | Mi Cancer Seek |
| Janssen Pharmaceuticals, INC | $21.44 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $18.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.63 | 2025 | Libtayo |
| Tempus Ai, INC | $17.04 | 2024 | Xt Cdx |
| Genentech USA, INC. | $14.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Villa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.